FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Wyeth dumps once-promising Curis collaboration

Tools

Back in 2004, Wyeth considered a project with Curis to develop small molecule and protein Hedgehog agonists--which promised new therapies for stroke and cardiovascular ailments--worth potentially more than $170 million in milestone payments.

That was then.

This morning, Curis announced that Wyeth is pulling out of the pact. "Our speculation is that Wyeth has decided to re-prioritize," a Curis spokesman told the Boston Globe. Curis pocketed a $3 million upfront payment in the Wyeth deal. Since then, Curis has repositioned itself as well, focusing on new cancer therapies.

- see this release from Curis
- read the story in the Boston Globe

Related Articles:
Curis halts trial for skin cancer therapy. Report
Curis halts enrollment on trial results. Report
Wyeth stumbles badly trying to develop new drugs. Report

More stories about molecules   Wyeth   protein   milestones   cancer therapies   Cancer   New Drugs   skin cancer  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.